This inventor holds 1 USPTO granted patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Keith Eagan: Innovator in Pharmaceutical Chemistry
Introduction
Keith Eagan is a notable inventor based in Kenilworth, NJ (US), recognized for his contributions to pharmaceutical chemistry. He holds a patent that focuses on novel heterocyclic compounds, specifically 4, 5, 6-trisubstituted pyrimidine derivatives, which serve as factor IXa inhibitors. His work is significant in the field of thromboembolic disorder treatment.
Latest Patents
Eagan's patent involves the development of compounds represented by Formula (I), which are described in detail in the patent documentation. These compounds, or their pharmaceutically acceptable salts, solvates, esters, prodrugs, or stereoisomers, are crucial for creating effective pharmaceutical compositions aimed at treating or preventing thromboembolic disorders.
Career Highlights
Keith Eagan is associated with Merck Sharp & Dohme Corporation, a leading global healthcare company. His role at Merck has allowed him to contribute significantly to the advancement of medical science through innovative drug development.
Collaborations
Eagan has collaborated with esteemed colleagues such as Mariappan Chelliah and Samuel Chackalamannil, enhancing the research and development efforts within his team.
Conclusion
Keith Eagan's work exemplifies the impact of innovation in pharmaceutical chemistry, particularly in developing treatments for thromboembolic disorders. His contributions continue to influence the field and improve patient outcomes.